8-K: BioAtla Reports Q2 2025 Results, Advances Clinical Programs

BioAtla, Inc. announced its second quarter 2025 financial results, showcasing reduced operating expenses and promising clinical progress for its lead oncology programs, BA3182 and Ozuriftamab vedotin.

Summary

• Reported Q2 2025 financial results and provided updates on ongoing clinical programs.
• Research and development (R&D) expenses decreased by $2.5 million to $13.7 million in Q2 2025, primarily due to a $1.2 million reduction in headcount, $0.6 million from program prioritization, and $0.6 million in lower non-cash stock-based compensation.
• General and administrative (G&A) expenses decreased by $0.8 million to $5.0 million in Q2 2025, driven by lower non-cash stock-based compensation and headcount reductions.
• Net loss for Q2 2025 was $18.7 million, an improvement from $21.1 million in Q2 2024.
• Net cash used in operating activities for the first six months of 2025 was $30.4 million, a significant reduction from $50.0 million in the same period of 2024.
• Cash and cash equivalents stood at $18.2 million as of June 30, 2025, down from $49.0 million at December 31, 2024.
• The Phase 1 dose-escalation study for BA3182 (CAB-EpCAM x CAB-CD3 TCE) is ongoing, with a data readout expected in the second half of 2025. Seven patients showed objective tumor size reductions, and prolonged progression-free intervals of 11 and 16 months were observed in two colorectal cancer patients.
• The Phase 2 study for Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC), a Fast Track Designated therapy, continues to show compelling antitumor activity in 2L+ HPV+ oropharyngeal squamous cell carcinoma (OPSCC), with an Objective Response Rate (ORR) of 45% (5/11) and a Disease Control Rate (DCR) of 100% (11/11).
• A meeting with the U.S. Food & Drug Administration (FDA) is planned for Q3 2025 to discuss the proposed Phase 3 study design for Ozuriftamab vedotin, which the company believes has potential for accelerated approval.
• The company is actively engaged in partnering discussions and remains confident in closing at least one transaction in 2025, with one partner already at the term-sheet stage.

Sentiment

Score: 6

Explanation: While financial metrics show improved efficiency (reduced burn, lower loss) and clinical data for Oz-V is very promising, the significant drop in cash and explicit 'going concern' warning are major concerns. The positive clinical data and partnering progress provide a counterbalance, suggesting potential for future value creation and funding.

Positives

• Reduced Research and Development (R&D) expenses by $2.5 million to $13.7 million in Q2 2025 compared to Q2 2024.
• Reduced General and Administrative (G&A) expenses by $0.8 million to $5.0 million in Q2 2025 compared to Q2 2024.
• Net loss decreased to $18.7 million in Q2 2025 from $21.1 million in Q2 2024.
• Net cash used in operating activities significantly decreased to $30.4 million for the first six months of 2025 from $50.0 million in the same period of 2024.
• BA3182 Phase 1 study showed objective tumor size reductions in seven patients, including NSCLC (-25%), cholangiocarcinoma (-13%), and breast (-11%).
• BA3182 Phase 1 study observed prolonged progression-free intervals of 11 months and 16 months in two colorectal cancer patients.
• Ozuriftamab vedotin (Oz-V) Phase 2 study demonstrated compelling antitumor activity in HPV+ OPSCC with an Objective Response Rate (ORR) of 45% (5/11) and a Disease Control Rate (DCR) of 100% (11/11).
• Oz-V's median duration of response was 9.9 months, median progression-free survival 4.7 months, and median overall survival 11.6 months (ongoing) in HPV+ OPSCC.
• Oz-V received Fast Track Designation from the FDA, indicating potential for expedited development and review.
• Company is advancing partnering discussions and is at the term-sheet stage with one partner, confident in closing at least one transaction in 2025.
• Management expects quarterly cash burn to decrease as Phase 2 trials conclude.

Negatives

• Cash and cash equivalents significantly decreased to $18.2 million as of June 30, 2025, from $49.0 million as of December 31, 2024.
• Total stockholders' equity moved into a deficit of $(16.745) million as of June 30, 2025, from a positive $14.265 million as of December 31, 2024.
• Workforce reduction announced in March 2025, indicating operational restructuring and associated costs of $0.6 million in Q2 2025.

Risks

• Factors raise substantial doubt about the ability to continue as a going concern.
• Need for additional funding to continue development of the CAB technology platform and product candidates.
• Potential delays in clinical and preclinical trials.
• Uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, or regulatory approval dates.
• Possibility of unfavorable new clinical data and further analyses of existing clinical data.
• Uncertainty whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies.
• Dependence on the success of the CAB technology platform.
• Ability to enroll patients in ongoing and future clinical trials.
• Successful selection and prioritization of assets to focus development on selected product candidates and indications.
• Ability to form collaborations and partnerships with third parties and the success of such collaborations and partnerships.
• Reliance on third parties for the manufacture and supply of product candidates for clinical trials.
• Reliance on third parties to conduct clinical trials and some aspects of research and preclinical testing.
• Potential adverse impacts due to geopolitical or macroeconomic events outside of control, including health epidemics or pandemics.

Future Outlook

Management expects Research and Development (R&D) expenses and quarterly cash burn to continue decreasing for the remainder of 2025 as Phase 2 trials for several indications conclude and development focuses on prioritized programs. The company anticipates closing at least one partnering transaction in 2025, with one already at the term-sheet stage. Positive data from the EpCAM Phase 1 trial and ongoing partnering discussions are expected to lead to transformational value creation. A Phase 1 data readout for BA3182 is expected in the second half of 2025, and cohort expansion data is anticipated in the first half of 2026. A meeting with the FDA is planned for Q3 2025 to discuss the proposed Phase 3 study design for Ozuriftamab vedotin, which the company believes has potential for accelerated approval.

Management Comments

• "We continue to be encouraged by the performance of our dual CAB EpCAM x CD3 bispecific TCE, BA3182, in Phase 1 and remain on track for an updated Phase 1 data readout later this year."
• "We are making encouraging progress with a partner at the term-sheet stage for one of our CAB assets, while continuing to advance partnering discussions across our portfolio, allowing us to maintain our guidance for a transaction this year."
• "We expect our R&D expenses to continue to decrease for the remainder of 2025 as we conclude our Phase 2 trials for several indications and focus our ongoing development on our prioritized programs."
• "We expect our quarterly cash burn to decrease as we near completion of our Phase 2 clinical trials for several indications."
• "The Company continues to take additional cash preservation measures by controlling expenses and monitoring encouraging progress for near-term milestone payments, while progressing partnership discussions that support key clinical activities and readouts."
• "These activities, along with positive data from our EpCAM Phase 1 trial, are expected to lead to transformational value creation."
• "Company believes Oz-V has the potential for accelerated approval."

Industry Context

BioAtla operates in the highly competitive and capital-intensive oncology biotechnology sector, focusing on conditionally active biologic (CAB) antibody therapeutics for solid tumors. Their proprietary CAB platform aims for more selective targeting and reduced toxicity compared to traditional antibodies. The positive Phase 2 data for Ozuriftamab vedotin in HPV+ oropharyngeal squamous cell carcinoma (OPSCC) is particularly notable, as this represents a sizable and rapidly growing patient population poorly served by existing standard of care regimens like EGFR inhibitors. The company's strategy to pursue partnering discussions is a common and crucial path for clinical-stage biotech companies to secure non-dilutive funding and leverage larger pharmaceutical companies' resources for late-stage development and commercialization, especially given their current cash position and the explicit 'going concern' risk.

Comparison to Industry Standards

• Ozuriftamab vedotin (Oz-V) monotherapy in 2L+ HPV+ oropharyngeal squamous cell carcinoma (OPSCC) demonstrated an Objective Response Rate (ORR) of 45% (5/11) and a median Overall Survival (OS) of 11.6 months (ongoing).
• This compares favorably to other studies using standard of care agents for HPV+ SCCHN patients, which reported an ORR of 3.4% and a median OS of 4.4 months, indicating Oz-V significantly outperforms current standard treatments in this specific patient population.
• The company's Conditionally Active Biologic (CAB) platform aims to deliver efficacy at least comparable to approved antibodies but with lower toxicities, potentially enabling safer combination therapies (e.g., Evalstotug with anti-PD-1) and broadening patient populations, which would be a significant advantage over existing therapies like traditional CTLA-4 inhibitors.

Stakeholder Impact

• Shareholders face potential for significant value creation if partnering deals materialize and clinical programs advance successfully, especially Oz-V's potential for accelerated approval. However, there is significant dilution risk due to the 'going concern' warning and need for additional funding, as current equity is in deficit.
• Employees experienced a workforce reduction in March 2025, indicating job losses but also a strategic effort to preserve cash and prioritize programs.
• Patients may benefit from promising clinical data for BA3182 and Ozuriftamab vedotin, which offers hope for new treatment options for advanced adenocarcinoma and HPV+ OPSCC, particularly for heavily pretreated patients with limited alternatives.
• Creditors face increased financial risk due to the explicit 'going concern' warning.

Next Steps

• Phase 1 data readout for BA3182 expected 2H 2025.
• Meeting planned with FDA in 3Q 2025 to discuss proposed Phase 3 study design for Ozuriftamab vedotin.
• Close at least one partnering transaction in 2025.
• Cohort expansion data readout for BA3182 anticipated 1H 2026.
• Presentation of BA3182 Phase 1 data at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting (October 17-21, 2025).
• Continue efforts to decrease R&D expenses and quarterly cash burn for the remainder of 2025.

Key Dates

Recommendation

The clinical data, particularly for Ozuriftamab vedotin, is highly encouraging and suggests significant potential for a challenging patient population. The company's efforts to reduce cash burn and pursue partnerships are positive steps. However, the substantial decline in cash reserves and the explicit 'going concern' warning present a significant financial risk. While there's upside potential from clinical milestones and partnerships, the immediate financial instability warrants caution. A 'hold' recommendation allows investors to monitor the progress of partnering discussions and the outcome of the FDA meeting, which are critical for addressing the funding needs and validating the clinical assets.

Keywords

Biotechnology, Oncology, Cancer Therapeutics, Antibody Drug Conjugate, Bispecific T-cell Engager, Conditionally Active Biologic, Clinical Trials, Phase 1, Phase 2, FDA Fast Track, Solid Tumors, EpCAM, CD3, ROR2, HPV+ OPSCC, Financial Results, SEC Filing